Efficacy and Safety Evaluation of SMO1 in Patients With Retinal Vein Occlusive Macular Edema

Inclusion Criteria: * 19 years of age or older * A study eye diagnosed with macular edema following i) branch retinal vein occlusion (BRVO) within 12 months prior to the screening visit or; ii) central retinal vein occlusion (CRVO) within 9 months prior to the screening visit * A study eye with CRT measured to be 300μm or greater using OCT at the screening visit * A study eye with BCVA between 34 and 68 letters at the screening visit and the baseline (comparable to Snellen score between 20/200 and 20/50) * Provided written informed consent voluntarily after receiving a full explanation of the clinical trial Exclusion Criteria: * A study eye with visual improvement determined to be highly unlikely due to the baseline condition of the eye * A study eye with macular edema caused by the formation of an epiretinal membrane or visual improvement determined to be highly unlikely even if the macular edema decreases * A study eye with uncontrolled glaucoma with intraocular pressure of 25mmHg or higher despite medical treatment at the screening visit * A study eye with severe media opacity such as corneal opacity, cataracts, or vitreous hemorrhage